Cassandra Casticimo

The Philippines has taken a significant step in addressing its growing mental health needs with the launch of lurasidone, a second-generation antipsychotic medication for schizophrenia and bipolar depression.

Photo Courtesy of PubChem.

Known as Latuda internationally, the drug is now available locally through a partnership between Wellesta Buergli and Sumitomo Pharma. 

Its official launch in Ortigas last April gathered mental health experts and advocates, who expressed optimism about its potential to improve psychiatric care in the country.

Mental illness remains a major public health issue in the Philippines, with over 3.6 million Filipinos experiencing mental, neurological, or substance use disorders. 

A 2020 World Health Organization (WHO) assessment revealed that major depressive disorder impacted over 1.1 million Filipinos, followed by bipolar disorder (520,000 cases) and schizophrenia (213,000). Despite these figures, many still lack access to effective treatment.

Lurasidone is an atypical antipsychotic that targets dopamine and serotonin, neurotransmitters responsible for mood, motivation, and perception. 

It works by blocking dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors, while partially activating the 5-HT1A receptor, helping reduce psychotic and depressive symptoms. 

Taken once daily with food, it may cause side effects like drowsiness, nausea, or movement issues, and patients are advised to stay hydrated and avoid heat.

Dr. Joan Mae Perez-Rifareal, president of the Philippine Psychiatric Association, welcomed lurasidone’s introduction, while Carla Aquino, country head of Wellesta, stressed the importance of expanding access to advanced treatments, especially for those with limited options.

Though not a cure-all, lurasidone provides a promising new option in the Philippines' mental health care landscape, offering hope for more manageable paths to wellness for many patients.